Cisen Pharmaceutical Co., Ltd. (SHA:603367)

Accolade Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Operating Revenue	3,743	3,972	4,451	4,049	3,773	3,666
Other Revenue	10.02	10.02	11.14	16.83	9.62	8.28
Revenue	3,753	3,982	4,462	4,066	3,783	3,674
Revenue Growth (YoY)	-16.17%	-10.77%	9.74%	7.50%	2.95%	-10.66%
Cost of Revenue	1,749	1,813	1,913	1,827	1,728	1,610
Gross Profit	2,003	2,168	2,550	2,239	2,055	2,064
Selling, General & Admin	1,242	1,367	1,600	1,544	1,455	1,355
Research & Development	316.21	342.64	374.88	335.17	334.35	309.58
Other Operating Expenses	9.96	-4.28	20.97	55.37	50.31	45.07
Operating Expenses	1,565	1,702	1,999	1,948	1,841	1,706
Operating Income	438.87	466.89	550.79	291.2	214.24	357.94
Interest Expense	-5.83	-6.95	-6.59	-4.29	-6.1	-9.8
Interest & Investment Income	113.07	101.87	85.7	53	90.18	83.09
Currency Exchange Gain (Loss)	0.54	0.54	0.55	-0.32	-0.62	-1.6
Other Non Operating Income (Expenses)	-2.56	-0.7	-1.27	-0.17	5.21	-3.55
EBT Excluding Unusual Items	544.09	561.66	629.19	339.41	302.91	426.09
Gain (Loss) on Sale of Investments	17.94	10.53	-10.37	-3.12	-6.09	23.03
Gain (Loss) on Sale of Assets	-2.22	-0.14	0.59	0.97	0.27	0.17
Asset Writedown	-12.35	-0.63	-27.79	0.01	-0.04	-1.05
Other Unusual Items	4.64	4.36	4.24	28.92	39.09	36.28
Pretax Income	552.1	575.77	595.86	366.19	336.13	484.52
Income Tax Expense	54.73	60.83	70.43	13.92	2.23	47.16
Earnings From Continuing Operations	497.37	514.94	525.43	352.27	333.9	437.36
Minority Interest in Earnings	-7.78	-6.03	-4.09	-2.31	0.24	1.42
Net Income	489.59	508.91	521.34	349.96	334.15	438.78
Net Income to Common	489.59	508.91	521.34	349.96	334.15	438.78
Net Income Growth	-7.34%	-2.38%	48.97%	4.73%	-23.85%	-14.73%
Shares Outstanding (Basic)	453	454	453	454	452	452
Shares Outstanding (Diluted)	453	454	453	454	452	452
Shares Change (YoY)	0.35%	0.23%	-0.25%	0.65%	-0.18%	0.21%
EPS (Basic)	1.08	1.12	1.15	0.77	0.74	0.97
EPS (Diluted)	1.08	1.12	1.15	0.77	0.74	0.97
EPS Growth	-7.66%	-2.61%	49.35%	4.05%	-23.71%	-14.91%
Free Cash Flow	295.56	469.04	433.53	223.15	182.58	228.74
Free Cash Flow Per Share	0.65	1.03	0.96	0.49	0.40	0.51
Dividend Per Share	0.440	0.440	0.436	0.335	0.300	0.256
Dividend Growth	0.92%	0.92%	30.15%	11.67%	17.19%	-4.48%
Gross Margin	53.38%	54.46%	57.14%	55.06%	54.32%	56.17%
Operating Margin	11.69%	11.73%	12.34%	7.16%	5.66%	9.74%
Profit Margin	13.05%	12.78%	11.68%	8.61%	8.83%	11.94%
Free Cash Flow Margin	7.88%	11.78%	9.71%	5.49%	4.83%	6.23%
EBITDA	651.73	683.33	781.54	519.77	432.08	517.92
EBITDA Margin	17.37%	17.16%	17.51%	12.78%	11.42%	14.10%
D&A For EBITDA	212.85	216.43	230.75	228.57	217.84	159.98
EBIT	438.87	466.89	550.79	291.2	214.24	357.94
EBIT Margin	11.69%	11.73%	12.34%	7.16%	5.66%	9.74%
Effective Tax Rate	9.91%	10.56%	11.82%	3.80%	0.66%	9.73%
Revenue as Reported	3,753	3,982	4,462	4,066	3,783	3,674
Advertising Expenses	-	1.47	0.82	0.2	0.51	2.83

Updated Oct 28, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.